PMID- 25228589
OWN - NLM
STAT- MEDLINE
DCOM- 20150806
LR  - 20211021
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 5
IP  - 17
DP  - 2014 Sep 15
TI  - Clinical outcomes of a novel combination of lenalidomide and rituximab followed 
      by stem cell transplantation for relapsed/refractory aggressive B-cell 
      non-hodgkin lymphoma.
PG  - 7368-80
AB  - We retrospectively compared outcomes of patients with relapsed/refractory 
      non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with 
      stable disease or better following a novel combination of lenalidomide and 
      rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical trial. 
      We retrospectively compared outcomes of patients who underwent SCT with that of 
      patients who had stable disease or better following LR treatment and did not 
      undergo SCT. Twenty-two patients enrolled in LR clinical trial and undergone SCT 
      were identified, 13 with mantle cell lymphoma (MCL) and nine with large B-cell 
      lymphoma (LBCL). All patients who underwent SCT achieved complete response. In 
      the MCL subset, there were no significant differences between SCT and non-SCT 
      groups except that non-SCT patients were older and had a higher mantle-cell 
      international prognostic index score. There was no difference between SCT-group 
      and non-SCT-group in response duration (P=0.3), progression-free survival (PFS) 
      (P=0.304) and overall survival (OS) (P=0.87). In LBCL subgroup, there were no 
      significant differences between two groups except that non-SCT group had a higher 
      international prognostic index score. Patients with LBCL who underwent SCT had 
      significantly longer response duration (P=0.001), PFS (P=0.000), and OS (P=0.003) 
      than the non-SCT group. The novel therapeutic combination offers a bridge to SCT 
      in patients with relapsed/refractory aggressive B-cell NHL.
FAU - Cai, Qingqing
AU  - Cai Q
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key 
      Laboratory of Oncology in South China; and Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, China. Department of Lymphoma and Myeloma, The 
      University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
FAU - Chen, Yiming
AU  - Chen Y
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Zou, Dehui
AU  - Zou D
AD  - Lymphoma and Myeloma Center, Institute of Hematology and Blood Diseases Hospital, 
      State Key Lab of Experimental Methods of Hematology, Chinese Academy of Medical 
      Sciences and Peking Union of Medical College, Tianjin, China.
FAU - Zhang, Liang
AU  - Zhang L
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Badillo, Maria
AU  - Badillo M
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Zhou, Shouhao
AU  - Zhou S
AD  - Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 
      Houston, Texas, USA.
FAU - Lopez, Elyse
AU  - Lopez E
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Jiang, Wenqi
AU  - Jiang W
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key 
      Laboratory of Oncology in South China; and Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, China.
FAU - Huang, Huiqiang
AU  - Huang H
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key 
      Laboratory of Oncology in South China; and Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, China.
FAU - Lin, Tongyu
AU  - Lin T
AD  - Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key 
      Laboratory of Oncology in South China; and Collaborative Innovation Center for 
      Cancer Medicine, Guangzhou, China.
FAU - Romaguera, Jorge
AU  - Romaguera J
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA.
FAU - Wang, Michael
AU  - Wang M
AD  - Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas, USA. Department of Stem Cell Transplantation and Cellular 
      Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 4Z8R6ORS6L (Thalidomide)
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Combined Modality Therapy
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lenalidomide
MH  - Lymphoma, B-Cell/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/mortality/*therapy
MH  - Retrospective Studies
MH  - Rituximab
MH  - Stem Cell Transplantation/*methods
MH  - Thalidomide/administration & dosage/analogs & derivatives
PMC - PMC4202129
EDAT- 2014/09/18 06:00
MHDA- 2015/08/08 06:00
PMCR- 2014/09/01
CRDT- 2014/09/18 06:00
PHST- 2014/09/18 06:00 [entrez]
PHST- 2014/09/18 06:00 [pubmed]
PHST- 2015/08/08 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - 2255 [pii]
AID - 10.18632/oncotarget.2255 [doi]
PST - ppublish
SO  - Oncotarget. 2014 Sep 15;5(17):7368-80. doi: 10.18632/oncotarget.2255.